Organon & Co. (OGN)
NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-11-04
$13.83-0.14%
Close 2026-11-04 · 1-day change
NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-11-04
QuarterlyIQ Insights · OGN
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -42.0% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| 3.7% |
Growth built into the price is above our model estimate.
The price assumes 45.7 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-04 · Compared with 10 industry peers · Company calendar date is not available
OGN — divestiture
Dated 2026-07-17
Other Events. As previously disclosed, on April 26, 2026, Organon & Co., a Delaware corporation (the “ Company ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) by and among the Company, Sun Pharmaceutical Holdings USA, Inc. (“ Sun Pharma USA ”), and Sun Pharma America, Inc., a wholly owned subsidiary of Sun Pharma USA (“ Merger Sub ”), and, solely for purposes of certain specified provisions of the Merger Agreement, Sun Pharmaceutical Industries Limited, Sun Pharma…
Why it matters: The stated goal is to keep results near 2025 levels. Full-year revenue will show whether the company met that aim.
Watch forFull-year 2026 revenue is near $6.2 billion or higher.
Also watch forFull-year 2026 revenue is below $6.2 billion, with Q4 revenue below the amount needed to reach that level.
Why it matters: Q1 revenue fell 9% after currency effects. The next release can show whether that decline eased or deepened.
Watch forThe Nov. 9 release reports revenue above $1.460 billion, the Q1 2026 level, and states year-over-year growth.
Also watch forThe Nov. 9 release reports revenue below $1.460 billion and a year-over-year decline.
Why it matters: Adjusted EBITDA fell in the first nine months of 2026. A further drop would show pressure on expense control and earnings.
Worry ifQ4 adjusted EBITDA is below the $518 million reported in Q4 2025.
Less concerning ifQ4 adjusted EBITDA is at least $518 million. This ends the year-over-year decline.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$14 on $10,000 · ±0.1% | How much price usually moves either way. |
| Bad day | $385 loss on $10,000 · 3.9% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,145 loss on $10,000 · 41.4% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.